402 related articles for article (PubMed ID: 30011276)
1. Identifying residual transmission of lymphatic filariasis after mass drug administration: Comparing school-based versus community-based surveillance - American Samoa, 2016.
Sheel M; Sheridan S; Gass K; Won K; Fuimaono S; Kirk M; Gonzales A; Hedtke SM; Graves PM; Lau CL
PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006583. PubMed ID: 30011276
[TBL] [Abstract][Full Text] [Related]
2. Potential strategies for strengthening surveillance of lymphatic filariasis in American Samoa after mass drug administration: Reducing 'number needed to test' by targeting older age groups, hotspots, and household members of infected persons.
Lau CL; Sheel M; Gass K; Fuimaono S; David MC; Won KY; Sheridan S; Graves PM
PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008916. PubMed ID: 33370264
[TBL] [Abstract][Full Text] [Related]
3. Comparison of antigen and antibody responses in repeat lymphatic filariasis transmission assessment surveys in American Samoa.
Won KY; Robinson K; Hamlin KL; Tufa J; Seespesara M; Wiegand RE; Gass K; Kubofcik J; Nutman TB; Lammie PJ; Fuimaono S
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006347. PubMed ID: 29522520
[TBL] [Abstract][Full Text] [Related]
4. Systematic sampling of adults as a sensitive means of detecting persistence of lymphatic filariasis following mass drug administration in Sri Lanka.
Rao RU; Samarasekera SD; Nagodavithana KC; Punchihewa MW; Ranasinghe USB; Weil GJ
PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007365. PubMed ID: 31009482
[TBL] [Abstract][Full Text] [Related]
5. Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration.
Lau CL; Sheridan S; Ryan S; Roineau M; Andreosso A; Fuimaono S; Tufa J; Graves PM
PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005914. PubMed ID: 28922418
[TBL] [Abstract][Full Text] [Related]
6. Seroprevalence and spatial epidemiology of Lymphatic Filariasis in American Samoa after successful mass drug administration.
Lau CL; Won KY; Becker L; Soares Magalhaes RJ; Fuimaono S; Melrose W; Lammie PJ; Graves PM
PLoS Negl Trop Dis; 2014; 8(11):e3297. PubMed ID: 25393716
[TBL] [Abstract][Full Text] [Related]
7. Lymphatic filariasis epidemiology in Samoa in 2018: Geographic clustering and higher antigen prevalence in older age groups.
Lau CL; Meder K; Mayfield HJ; Kearns T; McPherson B; Naseri T; Thomsen R; Hedtke SM; Sheridan S; Gass K; Graves PM
PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008927. PubMed ID: 33347456
[TBL] [Abstract][Full Text] [Related]
8. Lymphatic Filariasis Elimination in American Samoa: Evaluation of Molecular Xenomonitoring as a Surveillance Tool in the Endgame.
Lau CL; Won KY; Lammie PJ; Graves PM
PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005108. PubMed ID: 27802280
[TBL] [Abstract][Full Text] [Related]
9. How Thailand eliminated lymphatic filariasis as a public health problem.
Rojanapanus S; Toothong T; Boondej P; Thammapalo S; Khuanyoung N; Santabutr W; Prempree P; Gopinath D; Ramaiah KD
Infect Dis Poverty; 2019 May; 8(1):38. PubMed ID: 31130143
[TBL] [Abstract][Full Text] [Related]
10. Potential use of antibodies to provide an earlier indication of lymphatic filariasis resurgence in post-mass drug ad ministration surveillance in American Samoa.
Cadavid Restrepo AM; Gass K; Won KY; Sheel M; Robinson K; Graves PM; Fuimaono S; Lau CL
Int J Infect Dis; 2022 Apr; 117():378-386. PubMed ID: 35150913
[TBL] [Abstract][Full Text] [Related]
11. Ongoing transmission of lymphatic filariasis in Samoa 4.5 years after one round of triple-drug mass drug administration.
Mayfield HJ; Sartorius B; Sheridan S; Howlett M; Martin BM; Thomsen R; Tofaeono-Pifeleti R; Viali S; Graves PM; Lau CL
PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012236. PubMed ID: 38935622
[TBL] [Abstract][Full Text] [Related]
12. Lymphatic filariasis transmission in Rufiji District, southeastern Tanzania: infection status of the human population and mosquito vectors after twelve rounds of mass drug administration.
Jones C; Ngasala B; Derua YA; Tarimo D; Reimer L; Bockarie M; Malecela MN
Parasit Vectors; 2018 Nov; 11(1):588. PubMed ID: 30424781
[TBL] [Abstract][Full Text] [Related]
13. Towards elimination of lymphatic filariasis in southeastern Madagascar: Successes and challenges for interrupting transmission.
Garchitorena A; Raza-Fanomezanjanahary EM; Mioramalala SA; Chesnais CB; Ratsimbasoa CA; Ramarosata H; Bonds MH; Rabenantoandro H
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006780. PubMed ID: 30222758
[TBL] [Abstract][Full Text] [Related]
14. Molecular xenomonitoring as a post-MDA surveillance tool for global programme to eliminate lymphatic filariasis: Field validation in an evaluation unit in India.
Subramanian S; Jambulingam P; Krishnamoorthy K; Sivagnaname N; Sadanandane C; Vasuki V; Palaniswamy C; Vijayakumar B; Srividya A; Raju HKK
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007862. PubMed ID: 31978060
[TBL] [Abstract][Full Text] [Related]
15. Demographic, socioeconomic and disease knowledge factors, but not population mobility, associated with lymphatic filariasis infection in adult workers in American Samoa in 2014.
Graves PM; Sheridan S; Fuimaono S; Lau CL
Parasit Vectors; 2020 Mar; 13(1):125. PubMed ID: 32164780
[TBL] [Abstract][Full Text] [Related]
16. First evidence of lymphatic filariasis transmission interruption in Cameroon: Progress towards elimination.
Nana-Djeunga HC; Tchouakui M; Njitchouang GR; Tchatchueng-Mbougua JB; Nwane P; Domche A; Bopda J; Mbickmen-Tchana S; Akame J; Tarini A; Epée E; Biholong BD; Zhang Y; Tougoue JJ; Kabore A; Njiokou F; Kamgno J
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005633. PubMed ID: 28662054
[TBL] [Abstract][Full Text] [Related]
17. Reassessment of areas with persistent Lymphatic Filariasis nine years after cessation of mass drug administration in Sri Lanka.
Rao RU; Samarasekera SD; Nagodavithana KC; Dassanayaka TDM; Punchihewa MW; Ranasinghe USB; Weil GJ
PLoS Negl Trop Dis; 2017 Oct; 11(10):e0006066. PubMed ID: 29084213
[TBL] [Abstract][Full Text] [Related]
18. Is mass drug administration against lymphatic filariasis required in urban settings? The experience in Kano, Nigeria.
Pam DD; de Souza DK; D'Souza S; Opoku M; Sanda S; Nazaradden I; Anagbogu IN; Okoronkwo C; Davies E; Elhassan E; Molyneux DH; Bockarie MJ; Koudou BG
PLoS Negl Trop Dis; 2017 Oct; 11(10):e0006004. PubMed ID: 29020042
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of antigenemia and transmission intensity of Wuchereria bancrofti following cessation of mass drug administration in a formerly highly endemic region of Mali.
Coulibaly YI; Coulibaly SY; Dolo H; Konate S; Diallo AA; Doumbia SS; Soumaoro L; Coulibaly ME; Dicko I; Sangare MB; Dembele B; Sangare M; Dembele M; Touré YT; Kelly-Hope L; Polman K; Kyelem D; Traore SF; Bockarie M; Klion AD; Nutman TB
Parasit Vectors; 2016 Dec; 9(1):628. PubMed ID: 27912789
[TBL] [Abstract][Full Text] [Related]
20. Lymphatic filariasis elimination status: Wuchereria bancrofti infections in human populations and factors contributing to continued transmission after seven rounds of mass drug administration in Masasi District, Tanzania.
Lupenza ET; Gasarasi DB; Minzi OM
PLoS One; 2022; 17(1):e0262693. PubMed ID: 35045109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
